SEMA3A and pancreatic neuroendocrine tumor: The pro-invasive and pro-metastatic resistance detected upon angiogenesis reduction by the small-molecule tyrosine inhibitor sunitinib in pancreatic neuroendocrine tumors (PNETs) can be overwhelmed by SEMA3A expression [45].